Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
AMPLI Stock Overview
Amplitude Surgical SA develops and markets products for orthopedic surgery.
Amplitude Surgical Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €2.77 |
52 Week High | €2.80 |
52 Week Low | €1.95 |
Beta | 0.68 |
1 Month Change | 2.21% |
3 Month Change | 8.63% |
1 Year Change | 27.06% |
3 Year Change | 14.46% |
5 Year Change | -34.67% |
Change since IPO | -44.60% |
Recent News & Updates
Shareholder Returns
AMPLI | FR Medical Equipment | FR Market | |
---|---|---|---|
7D | 9.1% | 4.4% | -1.1% |
1Y | 27.1% | -5.8% | -5.9% |
Return vs Industry: AMPLI exceeded the French Medical Equipment industry which returned -5.8% over the past year.
Return vs Market: AMPLI exceeded the French Market which returned -5.9% over the past year.
Price Volatility
AMPLI volatility | |
---|---|
AMPLI Average Weekly Movement | 4.0% |
Medical Equipment Industry Average Movement | 7.0% |
Market Average Movement | 5.9% |
10% most volatile stocks in FR Market | 10.0% |
10% least volatile stocks in FR Market | 3.4% |
Stable Share Price: AMPLI is less volatile than 75% of French stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: AMPLI's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 453 | Olivier Jallabert | https://www.amplitude-surgical.com |
Amplitude Surgical SA develops and markets products for orthopedic surgery. The company provides a range of orthopedic products for primary and revision surgery aimed at treating pathologies of the hip, knee, and lower extremities primarily for foot and ankle surgery. It offers knee and hip prostheses and implants for the foot and ankle.
Amplitude Surgical Fundamentals Summary
AMPLI fundamental statistics | |
---|---|
Market Cap | €126.65m |
Earnings (TTM) | -€11.95m |
Revenue (TTM) | €97.69m |
1.4x
P/S Ratio-11.1x
P/E RatioIs AMPLI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AMPLI income statement (TTM) | |
---|---|
Revenue | €97.69m |
Cost of Revenue | €51.44m |
Gross Profit | €46.25m |
Other Expenses | €58.20m |
Earnings | -€11.95m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Oct 19, 2022
Earnings per share (EPS) | -0.25 |
Gross Margin | 47.35% |
Net Profit Margin | -12.23% |
Debt/Equity Ratio | 240.3% |
How did AMPLI perform over the long term?
See historical performance and comparisonValuation
Is Amplitude Surgical undervalued compared to its fair value and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
2.38x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AMPLI's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate AMPLI's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: AMPLI is unprofitable, so we can't compare its Price-To-Earnings Ratio to the French Medical Equipment industry average.
PE vs Market: AMPLI is unprofitable, so we can't compare its Price-To-Earnings Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AMPLI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AMPLI is overvalued based on its Price-To-Book Ratio (2.4x) compared to the FR Medical Equipment industry average (2.2x).
Future Growth
How is Amplitude Surgical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
-5.2%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Amplitude Surgical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has Amplitude Surgical performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-11.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AMPLI is currently unprofitable.
Growing Profit Margin: AMPLI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AMPLI is unprofitable, and losses have increased over the past 5 years at a rate of 11.5% per year.
Accelerating Growth: Unable to compare AMPLI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AMPLI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (22.5%).
Return on Equity
High ROE: AMPLI has a negative Return on Equity (-23%), as it is currently unprofitable.
Financial Health
How is Amplitude Surgical's financial position?
Financial Health Score
3/6Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: AMPLI's short term assets (€89.8M) exceed its short term liabilities (€38.0M).
Long Term Liabilities: AMPLI's short term assets (€89.8M) do not cover its long term liabilities (€168.8M).
Debt to Equity History and Analysis
Debt Level: AMPLI's net debt to equity ratio (195.1%) is considered high.
Reducing Debt: AMPLI's debt to equity ratio has increased from 92.8% to 240.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AMPLI has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: AMPLI has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 36.3% each year
Dividend
What is Amplitude Surgical current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AMPLI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AMPLI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AMPLI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AMPLI's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as AMPLI has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
3.8yrs
Average management tenure
CEO
Olivier Jallabert (53 yo)
25.33yrs
Tenure
€653,532
Compensation
Mr. Olivier Jallabert is a Founder of Amplitude Surgical SA and has been its Chief Executive Officer since June 10, 2015 and is Chairman of the Board. Mr. Jallabert is a Founder, Chief Executive Officer an...
CEO Compensation Analysis
Compensation vs Market: Olivier's total compensation ($USD700.16K) is above average for companies of similar size in the French market ($USD287.59K).
Compensation vs Earnings: Olivier's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: AMPLI's management team is considered experienced (3.8 years average tenure).
Board Members
Experienced Board: AMPLI's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Amplitude Surgical SA's employee growth, exchange listings and data sources
Key Information
- Name: Amplitude Surgical SA
- Ticker: AMPLI
- Exchange: ENXTPA
- Founded: 1997
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: €126.650m
- Shares outstanding: 47.97m
- Website: https://www.amplitude-surgical.com
Number of Employees
Location
- Amplitude Surgical SA
- 11, Cours Jacques Offenbach
- Valence
- Rhône-Alpes
- 26000
- France
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/05/27 00:00 |
End of Day Share Price | 2022/05/27 00:00 |
Earnings | 2021/12/31 |
Annual Earnings | 2021/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.